• 1
    Selkoe DJ (2001) Alzheimer’s disease: genes, proteins and therapies. Physiol Rev 81, 742761.
  • 2
    Tabaton M, Nunzi MG, Xue R, Usiak M, Autilio-Gambetti L & Gambetti P (1994) Soluble amyloid β-protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid. Biochem Biophys Res Commun 200, 15981603.
  • 3
    Vigo-Pelfrey C, Lee D, Keim PS, Lieberburg I & Schenk D (1993) Characterization of β-amyloid peptide from human cerebrospinal fluid. J Neurochem 61, 19651968.
  • 4
    Naslund J, Karlstrom AR, Tjernberg LO, Schierhorn A, Terenius L & Nordstedt C (1996) High-resolution separation of amyloid β-peptides: structural variants present in Alzheimer’s disease amyloid. J Neurochem 67, 294301.
  • 5
    Maler JM, Klafki HW, Paul S, Spitzer P, Groemer TW, Henkel AW, Esselmann H, Lewczuk P, Kornhuber J & Wiltfang J (2007) Urea-based two-dimensional electrophoresis of β-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 7, 38153820.
  • 6
    Bibl M, Esselmann H, Otto M, Lewczuk P, Cepek L, Ruther E, Kornhuber J & Wiltfang J (2004) Cerebrospinal fluid amyloid beta peptide patterns in Alzheimer’s disease patients and nondemented controls depend on sample pretreatment: indication of carrier-mediated epitope masking of amyloid beta peptides. Electrophoresis 25, 29122918.
  • 7
    Lewczuk P, Esselmann H, Bibl M, Beck G, Maler JM, Otto M, Kornhuber J & Wiltfang J (2004) Tau protein phosphorylated at threonine 181 in CSF as a neurochemical biomarker in Alzheimer’s disease: original data and review of the literature. J Mol Neurosci 23, 115122.
  • 8
    Lewczuk P, Esselmann H, Bibl M, Paul S, Svitek J, Miertschischk J, Meyrer R, Smirnov A, Maler JM, Klein C et al. (2004) Electrophoretic separation of amyloid β peptides in plasma. Electrophoresis 25, 33363343.
  • 9
    Lewczuk P, Esselmann H, Groemer TW, Bibl M, Maler JM, Steinacker P, Otto M, Kornhuber J & Wiltfang J (2004) Amyloid β peptides in cerebrospinal fluid as profiled with surface enhanced laser desorption/ionization time-of-flight mass spectrometry: evidence of novel biomarkers in Alzheimer’s disease. Biol Psychiatry 55, 524530.
  • 10
    Portelius E, Tran AJ, Andreasson U, Persson R, Brinkmalm G, Zetterberg H, Blennow K & Westman-Brinkmalm A (2007) Characterization of amyloid β peptides in cerebrospinal fluid by an automated immunoprecipitation procedure followed by mass spectrometry. J Proteome Res 6, 44334439.
  • 11
    Thorsell A, Portelius E, Blennow K & Westman-Brinkmalm A (2007) Evaluation of sample fractionation using micro-scale liquid-phase isoelectric focusing on mass spectrometric identification and quantitation of proteins in a SILAC experiment. Rapid Commun Mass Spectrom 21, 771778.
  • 12
    Bentahir M, Nyabi O, Verhamme J, Tolia A, Horre K, Wiltfang J, Esselmann H & De Strooper B (2006) Presenilin clinical mutations can affect gamma-secretase activity by different mechanisms. J Neurochem 96, 732742.
  • 13
    Hardy J & Allsop D (1991) Amyloid deposition as the central event in the aetiology of Alzheimer’s disease. Trends Pharmacol 12, 383388.
  • 14
    Selkoe DJ (1991) The molecular pathology of Alzheimer’s disease. Neuron 6, 487498.
  • 15
    Hardy J & Selkoe DJ (2002) The amyloid hypothesis of Alzheimer’s disease: progress and problems on the road to therapeutics. Science 297, 353356.
  • 16
    Walsh DM & Selkoe DJ (2007) Aβ oligomers – a decade of discovery. J Neurochem 101, 11721184.
  • 17
    Walsh DM, Hartley DM & Selkoe DJ (2003) The many faces of Aβ: structures and activity. Curr Med Chem Immunol Endocr Metab Agents 3, 277291.
  • 18
    Zarandi M, Soos K, Fulop L, Bozso Z, Datki Z, Toth GK & Penke B (2007) Synthesis of Aβ[1–42] and its derivatives with improved efficiency. J Pept Sci 13, 9499.
  • 19
    Tickler AK, Barrow CJ & Wade JD (2001) Improved preparation of amyloid β-peptides using DBU as Nalpha-Fmoc deprotection reagent. J Pept Sci 7, 488494.
  • 20
    Döbeli H, Draeger N, Huber G, Jakob P, Schmidt D, Seilheimer B, Stuber D, Wipf B & Zulauf M (1995) A biotechnological method provides access to aggregation-competent monomeric Alzheimer’s 1–42 residue amyloid peptide. Bio/Technology 13, 988993.
  • 21
    Lee EK, Hwang JH, Shin DY, Kim DI & Yoo YJ (2005) Production of recombinant amyloid β-peptide 42 as an ubiquitin extension. Protein Expr Purif 40, 183189.
  • 22
    Wiesehan K, Funke SA, Fries M & Willbold D (2007) Purification of recombinantly expressed and cytotoxic human amyloid β-peptide 1–42. J Chromatogr B Analyt Technol Biomed Life Sci 856, 229233.
  • 23
    Sharpe S, Yau WM & Tycko R (2005) Expression and purification of a recombinant peptide from the Alzheimer’s β-amyloid protein for solid-state NMR. Protein Expr Purif 42, 200210.
  • 24
    Liao YD, Jeng JC, Wang CF, Wang SC & Chang ST (2004) Removal of N-terminal methionine from recombinant proteins by engineered E. coli methionine aminopeptidase. Protein Sci 13, 18021810.
  • 25
    Walsh DM, Lomakin A, Benedek GB, Condron MM & Teplow DB (1997) Amyloid β-protein fibrillogenesis: detection of a protofibrillar intermediate. J Biol Chem 272, 2236422374.
  • 26
    Kametani F, Tanaka K, Tokuda T & Allsop D (1995) The immunoreactive profile at the N-terminal region of Aβ 1–39/40 but not Aβ 1–42 changes with transition from monomer/dimer to further peptide aggregates. Brain Res 703, 237241.
  • 27
    Wiltfang J, Smirnov A, Schnierstein B, Kelemen G, Matthies U, Klafki HW, Staufenbiel M, Huther G, Ruther E & Kornhuber J (1997) Improved electrophoretic separation and immunoblotting of β-amyloid (Aβ) peptides 1–40, 1–42, and 1–43. Electrophoresis 18, 527532.
  • 28
    Shevchenko A, Wilm M, Vorm O & Mann M (1996) Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 68, 850858.
  • 29
    Hepler RW, Grimm KM, Nahas DD, Breese R, Dodson EC, Acton P, Keller PM, Yeager M, Wang H, Shughrue P et al. (2006) Solution state characterization of amyloid β-derived diffusible ligands. Biochemistry 45, 1515715167.
  • 30
    Walsh DM, Hartley DM, Kusumoto Y, Fezoui Y, Condron MM, Lomakin A, Benedek GB, Selkoe DJ & Teplow DB (1999) Amyloid β-protein fibrillogenesis. Structure and biological activity of protofibrillar intermediates. J Biol Chem 274, 2594525952.
  • 31
    Levine H (1995) Thioflavin T interaction with amyloid beta-sheet structures. Amyloid Int J Exp Clin Invest 2, 16.
  • 32
    Naiki H & Nakakuki K (1996) First-order kinetic model of Alzheimer’s beta-amyloid fibril extension in vitro. Lab Invest 74, 374383.
  • 33
    Jarrett JT, Berger EP & Lansbury PT Jr (1993) The carboxy terminus of the beta amyloid protein is critical for the seeding of amyloid formation: implications for the pathogenesis of Alzheimer’s disease. Biochemistry 32, 46934697.
  • 34
    Walsh DM, Hartley DM, Condron MM, Selkoe DJ & Teplow DB (2001) In vitro studies of amyloid β-protein fibril assembly and toxicity provide clues to the aetiology of Flemish variant (Ala692[RIGHTWARDS ARROW]Gly) Alzheimer’s disease. Biochem J 355, 869877.
  • 35
    Harper JD, Wong SS, Lieber CM & Lansbury PT (1999) Assembly of Aβ amyloid protofibrils: an in vitro model for a possible early event in Alzheimer’s disease. Biochemistry 38, 89728980.
  • 36
    Glabe CG (2008) Structural classification of toxic amyloid oligomers. J Biol Chem 283, 2963929643.
  • 37
    Klein WL, Krafft GA & Finch CE (2001) Targeting small Abeta oligomers: the solution to an Alzheimer’s disease conundrum? Trends Neurosci 24, 219224.
  • 38
    Halverson K, Fraser PE, Kirschner DA & Lansbury PT Jr (1990) Molecular determinants of amyloid deposition in Alzheimer’s disease: conformational studies of synthetic beta-protein fragments. Biochemistry 29, 26392644.
  • 39
    Burdick D, Soreghan B, Kwon M, Kosmoski J, Knauer M, Henschen A, Yates J, Cotman C & Glabe C (1992) Assembly and aggregation properties of synthetic Alzheimer’s A4/β amyloid peptide analogs. J Biol Chem 267, 546554.
  • 40
    Wütrich K (1986) NMR of Proteins and Nucleic Acids. Wiley, New York, NY.
  • 41
    Zhang L, Yu H, Song C, Lin X, Chen B, Tan C, Cao G & Wang Z (2009) Expression, purification, and characterization of recombinant human β-amyloid42 peptide in Escherichia coli. Protein Expr Purif 64, 5562.
  • 42
    Subramanian S & Shree A (2007) Expression, purification and characterization of a synthetic gene encoding human amyloid β (Aβ1–42) in Escherichia coli. Indian J Biochem Biophys 44, 7175.
  • 43
    Brodin P, Grundstrom T, Hofmann T, Drakenberg T, Thulin E & Forsen S (1986) Expression of bovine intestinal calcium binding protein from a synthetic gene in Escherichia coli and characterization of the product. Biochemistry 25, 53715377.
  • 44
    Nilsberth C, Westlind-Danielsson A, Eckman CB, Condron MM, Axelman K, Forsell C, Stenh C, Luthman J, Teplow DB, Younkin SG et al. (2001) The ‘Arctic’ APP mutation (E693G) causes Alzheimer’s disease by enhanced Aβ protofibril formation. Nat Neurosci 4, 887893.
  • 45
    Levy E, Carman MD, Fernandez-Madrid IJ, Power MD, Lieberburg I, van Duinen SG, Bots GTAM, Luyendijk W & Frangione B (1990) Mutation of the Alzheimer’s disease amyloid gene in hereditary cerebral hemorrhage, Dutch-type. Science 248, 11241126.
  • 46
    Hendriks L, van Duijn CM, Cras P, Cruts M, Van Hul W, van Harskamp F, Warren A, McInnis MG, Antonarakis SE, Martin J-J et al. (1992) Presenile dementia and cerebral haemorrhage linked to a mutation at codon 692 of the β-amyloid precursor protein gene. Nat Genet 1, 218221.
  • 47
    Kamino K, Orr HT, Payami H, Wijsman EM, Alonso E, Pulst SM, Anderson L, O’dahl S, Nemens E, White JA et al. (1992) Linkage and mutational analysis of familial Alzheimer disease kindreds for the APP gene region. Am J Hum Genet 51, 9981014.
  • 48
    Bugiani O, Padovani A, Magoni M, Andora G, Sgarzi M, Savoiardo M, Bizzi A, Giaccone G, Rossi G & Tagliavini F (1998) An Italian type of HCHWA. Neurobiol Aging 19, S238.
  • 49
    Betts V, Leissring ML, Dolios G, Wang R, Selkoe DJ & Walsh DM (2008) Aggregation and catabolism of disease-associated intra-Aβ mutations: reduced proteolysis of AβA21G by neprilysin. Neurobiol Dis 31, 442450.